Table 2. Plasma TG (mg per 100 ml) and FFA (mM) in ACS-transgenic mice before and at 7 days and 8 weeks after treatment with AdCMV-leptin or AdCMV-β-gal and in age-matched untreated wild-type controls.
| Time after baseline
|
|||||
|---|---|---|---|---|---|
| Genotype | Treatment | TG/FFA | Baseline | 7 days | 8 weeks |
| ACS-transgenic (n = 6) | AdCMV-β-gal | TG | 105 ± 10.5 | 100 ± 12.1 | 92 ± 19.3 |
| FFA | 0.80 ± 0.16 | 0.78 ± 0.12 | 0.54 ± 0.05 | ||
| AdCMV-leptin | TG | 98 ± 6.5 | 39 ± 3.1 | 37 ± 2.8 | |
| FFA | 0.82 ± 0.05 | 0.35 ± 0.07 | 0.15 ± 0.03 | ||
| Wildtype (n = 6) | None | TG | 100 ± 5.2 | 103 ± 7.2 | 83 ± 8.4 |
| FFA | 1.00 ± 0.10 | 1.07 ± 0.13 | 1.45 ± 0.07 | ||